Cargando...
Systematic review and meta-analysis of the benefit of celecoxib in treating advanced non-small-cell lung cancer
BACKGROUND: The clinical benefit of a selective cyclooxygenase-2 inhibitor, celecoxib, combined with anticancer therapy in advanced non-small-cell lung cancer (NSCLC) remains unclear. A meta-analysis was performed to address the efficacy and safety of celecoxib in patients with advanced NSCLC. MATER...
Gardado en:
| Publicado en: | Drug Des Devel Ther |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Dove Medical Press
2018
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6086108/ https://ncbi.nlm.nih.gov/pubmed/30122902 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S169627 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|